Program
cadisegliatin
Also written as “GK1-399 (formerly TTP399)”, “Cadisegliatin 800 mg QD” and “TTP399”.
Its studies are mostly in Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2, led by vTv Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| vTv Therapeutics | 52 open or running | phase 3since Mar 13, 2024 | Nov 15, 2011 | Apr 2027phase 3 · NCT06334133 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 15, 2011First study: phase 2 study in Diabetes Mellitus, Type 2First studyNCT01474083 · 248 enrolled · United States
- Mar 27, 2015Phase 2 study in Diabetes Mellitus, Type 2NCT02405260 · 190 enrolled · United States
- Oct 31, 2017Phase 2 study in Diabetes Mellitus, Type 1NCT03335371 · 115 enrolled · United States
- Mar 13, 2024Phase 3 study in Diabetes Mellitus, Type 1NCT06334133 · 150 enrolled · United States, Puerto Rico
- May 15, 2026Phase 2 study in Diabetes Mellitus, Type 1NCT07616206 · 40 planned · United States
Ahead
- Apr 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 1NCT06334133
- Jun 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 1NCT07616206
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07616206Diabetes Mellitus, Type 1 · United States | 2 | Recruiting | Jun 2027 | 40 |
| NCT06334133Diabetes Mellitus, Type 1 · United States, Puerto Rico | 3 | Active, not recruiting | Apr 2027 | 150 |
| NCT03335371Diabetes Mellitus, Type 1 · United States | 2 | Completed | Dec 20, 2019 | 115 |
| NCT02405260Diabetes Mellitus, Type 2 · United States | 2 | Completed | Jul 2016 | 190 |
| NCT01474083Diabetes Mellitus, Type 2 · United States | 2 | Completed | Aug 2012 | 248 |
How it is read
Names in the registry
- “GK1-399 (formerly TTP399)”, 3 entries
- “Cadisegliatin 800 mg QD”, 2 entries
- “TTP399”, 2 entries
- “Cadisegliatin 800 mg BID”, 1 entry
- “TTP399 400 mg”, 1 entry
Codes read as this program: TTP399.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 1, 3 studies
- Diabetes Mellitus, Type 2, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.